High infection rates and a better understanding of underlying health impact increase the demand for screening for STI organisms including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), Herpes Simplex Virus 1 & 2 (HSV1 & HSV2)*, and Human Papillomavirus (HPV)* in targeted populations around the world.

This demand comes at a time when laboratories are challenged by the pressure to contain healthcare costs, a shortage of trained personnel and expectations to deliver more, and higher quality results.

BD has developed solutions that fulfill your screening and diagnostic needs with :

• A clinically relevant menu
• A range of molecular systems
• Superior laboratory productivity and efficiency with Lean & "Six sigma" methodologies